We report the preparation of polymer capsules containing liposomal subcompartments, termed capsosomes, and their ability for the sustained delivery of protein therapeutics.
INTRODUCTION
With advancements in biotechnology, the number of protein pharmaceutics have dramatically increased, improving the treatment of previously hard-to-treat diseases. 1 Compared to synthetic small molecules, protein therapeutics have a significant advantage due to their specific mechanism of action and high potency. 1, 2 However, the poor pharmacokinetics of protein therapeutics and their susceptibility to degradation present clinical challenges for their successful delivery. 3 For example, oral administration can result in digestion of the protein in the gastrointestinal tract, while intravenous injection can result in degradation of the protein by proteases in the blood or in capture of the protein by receptors and non-specific binding sites. 4 As a result, different delivery approaches have been developed to circumvent the challenges related to protein delivery.
To date, the two most prominent techniques for improving the delivery of protein therapeutics are PEGylation 5, 6 and incorporation of the proteins into biocompatible carriers. 7, 8 PEGylation, the chemical attachment of poly(ethylene glycol) (PEG) to proteins, can enhance overall protein efficacy by masking antigenic sites, thus reducing the formation of neutralizing antibodies. 2 The PEG shell also protects the proteins from proteolytic degradation by proteases present in the bloodstream. Finally, it improves the solubility and increases the hydrodynamic radius of the proteins, which reduces glomerular filtration. The major drawback of PEGylation, however, is the reduction in protein activity that commonly follows chemical modification of the protein. 2 In addition, PEG is not biodegradable and 3 long-term usage may lead to accumulation in the liver, which could increase the risk of toxicity. 8 Alternatively, a wide variety of carriers have also been evaluated for protein delivery, including polymeric particles, hydrogels, and liposomes. 2, 4, 9 Poly(lactic-co-glycolic acid) (PLGA)-based systems are among the most successful polymeric carriers, with numerous iterations, such as Lupron depot, Nutropin depot and Decapeptyl, being already available on the market. 1, 7 The success of PLGA stems from its high biocompatibility and biodegradability. 7 The physical properties and biodegradability of PLGA can also be tuned to fit specific applications by varying the molecular weight and the ratio of lactic acid to glycolic acid. 10 However, PLGA still suffers from some drawbacks, such as hydrophobicity, an acidic microenvironment during degradation, and chemical reactivity with some protein therapeutics. Subsequently, the sample was purified by centrifugation at 14 000 g for 20 min using a Nanosep spin column (MWCO = 3 kDa) to remove the unreacted dye. The labeled lysozyme was then redispersed in 3 mL of Milli-Q water and the protein concentration was determined 6 using a NanoDrop 1000 UV/VIS spectrophotometer. The same protocol was followed for labeling the BDNF with a F/P ratio of approximately 1.
Liposome Formation. Liposomes were prepared by a thin film hydration technique using Table S1 .
Assembly of Multilayer Capsosomes. Capsosomes were assembled using a previously reported procedure. 19 Briefly, 5 mg of silica templates (2.59 µm in diameter) were washed three times (1000 g for 30 s) using HEPES buffer. The particles were then suspended in 100 µL of PLL (1 mg mL -1 ) and incubated for 15 min to allow PLL to form a precursor layer on the silica templates. The PLL-coated particles were then washed three times with HEPES buffer. Lysozyme-or BDNF-loaded liposomes (100 µL) was added to the particles, vortexed for 30 s and incubated for 45 min. The particles were then washed three times to remove 
RESULTS AND DISCUSSION

Lysozyme-loaded multilayer capsosomes
The assembly of multilayer capsosomes was performed based on our previously optimized protocol, via the sequential adsorption of polymer and liposome layers onto silica particle templates. 19 A PLL precursor layer was first adsorbed onto silica particles, followed by the deposition of fluorescently labeled protein-loaded liposomes. PMA c was used as a polymer separation layer to enable consecutive adsorption of zwitterionic saturated liposome layers (Scheme 1). Protein release studies were conducted by incubating the lysozyme-FITC-loaded capsosomes in PBS buffer (pH 7.4) and monitoring the amount of protein in the supernatant over time using spectrofluorometry. Overall, the capsosomes exhibited a two-phase release profile, where rapid release was observed within the first 7 days followed by a sustained release of lysozyme for more than 2 months (Figure 3 ). An increased content of saturated gel phase lipid (DPPC) resulted in a significant reduction in the initial burst release; the total release of lysozyme over 7 days decreased from ca. 70% for capsosomes with DMPC/DPPC liposomes to ca. 40% for capsosomes with DPPC liposomes. This demonstrates that the permeability of liposomes to water soluble cargo can be controlled by varying the ratio of a more rigid lipid bilayer (DPPC) to that of a more fluid lipid bilayer (DMPC). [27] [28] [29] Increasing the content of DPPC, which forms a more rigid membrane as a result of stronger intermolecular forces between the phospholipid bilayers, 30 
BDNF-loaded multilayer capsosomes
After demonstrating the potential of capsosomes as long-term delivery vehicles for protein cargo, we further assessed the loading capacity and release profile of BDNF, a physiologically relevant protein therapeutic, from multilayer capsosomes. In this study, Figure 4a ). This is an appropriate loading capacity, as 4-7 ng of BDNF has been found to be sufficient to elicit a positive therapeutic outcome, indicating that only thousands of 14 capsosomes would be required. 24 However, for the release experiments higher amounts were used to ensure the therapeutic efficacy remained over a prolonged period. In all of the liposome formulations studied, the capsosomes had a relatively higher loading capacity for BDNF in comparison to lysozyme (Figure 2 ). This is likely due to the relatively larger dimeric molecular structure of BDNF, 31 an observation consistent with our previous study where capsosomes were observed to exhibit size dependent retention of water soluble cargo. 19 Fluorescence microscopy images of capsosomes encapsulating BDNF-FITC in the liposomal compartments are shown in Figure 4b .
The release profiles of BDNF from these multilayer capsosomes were investigated at physiological conditions over time, at both 4 °C and 37 °C. The capsosomes exhibited longterm release behavior, with the total amount of BDNF not fully released after 80 days. The inclusion of anionic DOPS similarly resulted in a reduction in the release rate of the proteins during the first release phase over 7 days ( Figure 5 ). The total release of BDNF from capsosomes with DMPC/DPPC/DOPS liposomes over 7 days was determined to be ca. 30%, compared with ca. 40% for capsosomes with DPPC liposomes. The influence of saturated gel phase lipid DPPC in tuning the release profile was well illustrated by comparing the release of BDNF at 37 °C to those at 4 °C. Over a two-month period, capsosomes with DPPC liposomes released less than 25% of the encapsulated BDNF at 4 ºC, compared with ca. 60% release at 37 °C. The DPPC lipid bilayers were more tightly packed at 4 °C than at 37 °C due to a reduction in thermal vibrations; this resulted in enhanced intermolecular attraction and hence stronger resistance to protein diffusion. 
